| Title |
|
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
Anti-tumor necrosis factor |
|
|
Secondary loss of response |
|
|
Therapeutic drug monitoring |
|
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
| Abstract |
|
The optimal infliximab dose intensification strategy to address secondary loss of response (LOR) remains unclear. This study aimed to compare clinical and pharmacokinetic outcomes following (i) upfront infliximab re-induction with (ii) ongoing 6-weekly dose interval shortening (DIS), after the same number of doses. |
|
|
| Link |
|
| Citation |
|
Journal of Gastroenterology and Hepatology 2023-05; 38(5) |
|
|
| Jornal Title |
|
Journal of Gastroenterology and Hepatology |
|
|
| ISSN |
|
